Safety, efficacy and patient satisfaction with continuous daily administration of levonorgestrel/ethinylestradiol oral contraceptives

Patient Preference and Adherence

Volumn 3, Issue , 2009, Pages 131-143

  Benagiano, Giuseppe ^a   Carrara, Sabina ^a   Filippi, Valentina ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Amenorrhea; Continuous administration; Levonorgestrel; Menstruation; Oral contraceptive

Indexed keywords

EID: 78649518675     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S3692     Document Type: Review

References (89)

1. Goldzieher JW, Rudel HW. How the oral contraceptives came to be developed. J Am Med Assoc. 1974;230:421-425.
2. Diczfalusy E. The contraceptive revolution. Caserton Hall: The Parthenon Publishing Group; 1997.
3. Benagiano G, Isidori C. Le basi razionali per l'utilizzazione clinica di una associazione estro-progestinica contenente Gestodene. In: Aggiornamenti in scienze ginecologiche ed ostetriche. Fioretti P, Melis GB Editors. Roma: CIC Edizioni Internazionali; 1987. p. 295-304.
4. Benagiano G, Farris M, Primiero FM. Clinical profile of contraceptive progestins. Eur J Contracept Reprod Health Care. 2004;9:182-193.
5. Ware RS. New progestagens for contraceptive use. Hum Reprod Update. 2006;2:169-178.
6. Smith CL, O'Malley BW. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev. 2004;25:45-71.
7. Chabbert-Buffet N, Meduri G, Bouchard P, Spitz IM. Selective progesterone receptor modulators and progesterone antagonist: mechanism of action and clinical applications. Hum Reprod Update. 2005; 11(3):293-307.
8. Spitz IM, Chwalisz K. Progesterone receptor modulators and progesterone antagonists in women's health. Steroids. 2000;65:807-815.
9. Chwalisz K, Perez MC, DeManno D, Winkel C, Schubert G, Elger W. Selective Progesterone Receptor Modulator. Development and Use in the Treatment of Leiomyomata and Endometriosis. Endocrine Rev. 2005;26:423-438.
10. Spitz IM, Croxatto HB, Robbins A. Antiprogestins: mechanism of action and contraceptive potential. Annu Rev Pharmacol Toxicol. 1996;36:47-81.
11. Schering AG. Hormonal Contraception. 3rd Ed. London: Butler & Tanner; 2001. p. 109.
12. Stanczyk FZ, Roy S. Metabolism of levonorgestrel, norethindrone, and structurally related contraceptive steroids. Contraception. 1990;42:67-96.
13. Sanchez-Borregol R, Balasci J. Ethinyl oestradiol plus dl-norgestrel or levonorgestrel in the Yuzpe method for post-coital contraception: results of an observational study. Hum Reprod. 1996;11:2449-2453.
14. Fotherby K, Caldwell ADS. New progestogens in oral contraception. Contraception. 1994;49:1-31.
15. Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas. 2003;46 Suppl 1:S7-S16.
16. Stanczyk FZ. Structure-function relationships, potency, and pharmacokinetics of progestogens. In: Lobo RA, editor. Treatment of the postmenopausal woman: basic and clinical aspects. New York: Raven Press; 1994. p. 69-89.
17. Scleusser E, Broeckner T, Brautigam J, Michaels W. Influence of two low dose oral contraceptives on possible gonadotropin secretion. Gynecol Endocrinol. 2001;15:259-264.
18. Anderson FD, Hait H, Hsiu J, Thompson-Graves AL, Wilborn WH, Williams RF. et al. Endometrial microstructure after long-term use of a 91-day extended-cycle oral contraceptive regimen. Contraception. 2005;71:55-59.
19. Guttinger A, Critchley HO. Endometrial effects of intrauterine levonorgestrel. Contraception. 2007;75 Suppl 6:S93-S98.
20. Luukkainen T. Levonorgestrel-releasing intrauterine device. Ann NY Acad Sci. 1991;626:43-49.
21. Dunson TR, Blumenthal PD, Alvarez F, et al. Timing of onset of contraceptive effectiveness in Norplant implant users. Changes in cervical mucus. Fertil Steril. 1998;69:258-266.
22. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet. 1995;346:1575-1582.
23. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombo-embolism. BMJ. 2001;323:1-9.
24. Sartwell PE, Masi AP, Arthes G, et al. Thromboembolism and oral contraceptives: an epidemiologic case-control study. Am J Epidemiol. 1969;90:365-380.
25. Martínez F, Avecilla A. Combined hormonal contraception and venous thromboembolism. Eur J Contracept Reprod Health Care. 2007;12:97-106.
26. Endrikat J, Hite R, Bannemerschult R, Gerlinger C, Schmidt W. et al. Multicenter, comparative study of cycle control, efficacy and tolerability of two low-dose oral contraceptives containing 20 mcg ethinylestradiol/100 mcg levonorgestrel and 20 mcg ethinylestradiol/500 mcg norethisterone. Contraception. 2001;64:3-10.
27. Reisman H, Martin D, Gast MJ. A multicenter randomized comparison of cycle control and laboratory findings with oral contraceptive agents containing 100 mcg levonorgestrel with 20 mcg ethinyl estradiol or triphasic norethindrone with ethinyl estradiol. Am J Obstet Gynecol. 1999;181:45-52.
28. Chavez A, DelConte A. A comparison of cycle control with monophasic levonorgestrel/ethinylestradiol 100 micrograms/20 micrograms versus triphasic norethindrone/ethinylestradiol 500-750-1000 micrograms/35 micrograms: a multicenter, randomized, open label study. Eur J Contracept Reprod Health Care. 1999;4: 75-83.
29. Pincus, G. Control of fertility. New York and London: Academic Press; 1965. p. 219.
30. The ESHRE Capri Workshop Group; Apter D, Baird DT, Collins J, et al. Report prepared by Collins J, Crosignani PG. Endometrial bleeding. Hum Reprod Update. 2007;13:421-431.
31. Finn CA. Implantation, menstruation and inflammation. Biol Rev. 1986;61:313-328.
32. Lin K, Banhart K. The clinical rationale for menses-free contraception. J Womens Health (Larchmt). 2007;16:1171-1180.
33. Drife JO. Menstruation: a cultural and historical perspective. In: Cameron IT, Fraser IS, Smith SK, Editors. Clinical disorders of the endometrium and the menstrual cycle. Oxford and London: Oxford University Press; 1998. p. 312.
34. O'Grady K. Canadian Women's Health. Available from: http// www. cwhn.ca.
35. Coutinho EM, Segal SJ. Is menstruation obsolete? New York: Oxford University Press; 1999.
36. Berkowitz B. Cultural aspects in the care of the orthodox Jewish woman. J Midwifery Womens Health. 2008;53:62-67.
37. Dhami S, Sheikh A. The Muslim family: predicament and promise. West J Med. 2000;173:352-356.
38. Profet M. Mestruation as a defence against pathogen transported by sperm. Q Rev Biol. 1993;68:335-386.
39. Sulak PJ. Continuous oral contraception: changing times. Best Pract Res Clin Obstet Gynaecol. 2007;20:1-20.
40. Strassmann BI, Gillespie B. Life-history theory, fertility and reproductive success in humans. Proc R Soc Lond B. 2002;262:553-562.
41. Houppert K. The curse: confronting the last unmentionable taboo: Menstruation. New York: Ferrar, Straus and Giroux; 1999.
42. Strassmann BI. The Evolution of endometrial cycle and menstruation. Q Rev Biol. 1996;71:181-220.
43. Strassmann BI. Energy economy in the evolution of menstruation. Evol Anthropol. 1997;5:158-164.
44. Eaton SB, Wood JW, Pike MC, et al. Women's reproductive cancers in evolutionary context. Quart Rev Biol. 1994;69:353-367.
45. Segal, SJ. Preface to Coutinho EM, Segal SJ. Is menstruation obsolete? New York: Oxford University Press; 1999. p. XIII.
46. Martin E. The woman in the body: a cultural analysis of reproduction. Boston: Beacon Press; 1987.
47. Garside D, Gann PH, Gapstur SM, et al. the effects of a low-fat/ high-fiber diet on sex hormone levels and menstrual cycling in premenopausal women. Wiley InterScience. 2004;98:1870-1879.
48. Pincus G, Garcia CR, Rock J. Effects of certain 19-nor-steroids on the normal human menstrual cycle. Science. 1956;124:891-893.
49. World Health Organisation Task Force on Psychosocial Research in Family Planning Geneva. WHO; 1981.
50. Pardthaisong T. McDaniel EB, Gray RH. Acceptance and use of Depo Provera in Chieng Mai. IPPF Med Bull. 1975;9:1-3.
51. Edelman A, Lew R, Cwiak C, Nichols M, Jensen J. Acceptability of contraceptive-induced amenorrhea in a racially diverse group of US women. Contraception. 2007;75:450-453.
52. Kaunitz AM. Menstruation: choosing whether. and when. Contraception. 2000;62:277-284.
53. Glasier AF, Smith KB, van der Spuy ZM, et al. Amenorrhea associated with contraception-an international study on acceptability. Contraception. 2003;67:1-8.
54. Snow R, Hardyb E, Kneuperc E, et al. Women's responses to menses and non-bleeding intervals in the USA, Brazil and Germany. Contraception. 2007;76:23-29.
55. Tonkelaar I, Oddens BJ. Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraception use, and hormone replacement therapy use. Contraception. 1999;59:357-362.
56. SOFRES. Reproduction Humaine et Hormones, Symptômes liés au cycle: doivent-ils rester une fatalité? Résultat d'une grande enquête miroir TNS Sofres, Médecins/patientes sur l'attitude vis à vis des règles et la prise en charge des symptômes liés aux cycles. SOFRES Survey. 2006;19(no. 8 Spécial):1-11.
57. Ferrero S, Abbamonte LH, Giordano M, et al. What is the desired menstrual frequency of women without menstruation-related symptoms? Contraception. 2006;73:537-541.
58. Wiegratz I, Hommel HH, Zimmermann T, Kuhl H. Attitude of German women and gynecologists towards long-cycle treatment with oral contraceptives. Contraception. 2004;69:37-42
59. Sánchez-Borrego R, García-Calvo C. Spanish women's attitudes towards menstruation and use of a continuous, daily use hormonal combined contraceptive regimen. Contraception. 2008;77:114-117.
60. Abraham S, Fraser I, Gebski V, et al. Menstruation, menstrual protection and menstrual cycle problems. The knowledge, attitudes and practices of young Australian women. Med J Aust. 1985;142: 247-251.
61. Loudon NB, Foxwell M, Potts DM, Guild AL, Short RV. Acceptability of an oral contraceptive that reduces the frequency of menstruation: the tri-cycle pill regimen. Br Med J. 1977;2:487-490.
62. Sullivan H, Furniss H, Spona J, Elstein M. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 2g) and ethinyl estradiol (15 eg) on ovarian activity. Fertil Steril. 1999;72: 115-120.
63. Bachman G, Sulak PJ, Sampson-Landers C, et al. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone. Contraception. 2004;70:191-198.
64. Nakajima ST, Archer DF, Ellman H. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 mg (Loestrin-24 Fe). Contraception. 2007;75:16-22.
65. Thomas SL, Ellertson C. Nuisance or natural healthy: should monthly menstruation be optional for women? Lancet. 2000;355:922-924.
66. Andrist LC, Arias RD, Nucatola D, et al. Women's and providers' attitudes toward menstrual suppression with extended use of oral contraceptives. Contraception. 2004;70:359-363.
67. Benagiano G, Pera A, Bianchi P. Management of endometriosis: Historical background and rationale for the use of steroid hormones. In: Lemay A, Maheux R, Editors. Understanding and managing endometriosis. Advances in research and practice. New York: Parthenon Publishing; 1999. p. 211-218.
68. Vercellini P, De Giorgi O, Mosconi P, Stellato G, Vicentini G, Crosignani PG. Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis. Fertil Steril. 2002; 77:52-61.
69. MacGregor A. Migraine associated with menstruation. Funct Neurol. 2000;15:143-153.
70. Martin-Johnston MK, Okoji OY, Armstrong A. Therapeutic amenorrhea in patients at risk for thrombocytopenia. Obstet Gynecol Surv. 2008;63:395-402.
71. Miller L. Continuous administration of 100 mcg levonorgestrel and 20 mcg ethinyl estradiol for elimination of menses: a randomized trial. Obstet Gynecol. 2001;97:S16.
72. Kaunitz AM. Beyond the pill: New data and options in hormonal and intrauterine contraception. Am J Obstet Gynecol. 2005;192:998-1004.
73. Anderson FD, Hait H. and The Seasonale-301 Study Group. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception. 2003;68:89-96.
74. Anderson FD, Gibbons W, Portman D. Long-term safety of an extendedcycle oral contraceptive (Seasonale): a 2-year multicenter open-label extension trial. Am J Obstet Gynecol. 2006;195:92-96.
75. Anderson FD, Gibbons W, Portman D. Safety and efficacy of an extended regimen oral contraceptive utilizing continous low-dose ethinyl estradiol. Contraception. 2006;73:229-234.
76. De Berardis D, Serroni N, Salerno RM, Ferro FM. Treatment of premenstrual dysphoric disorder (PMDD) with a novel formulation of drospirenone and ethinyl estradiol. Ther Clin Risk Manag. 2007;3: 585-590.
77. Fenton C, Wellington K, Moen-Robinson D.M. Drospirenone/ethinylestradiol 3 mg/20 microg (24/4 day regimen): a review of its use in contraception, premenstual dysphoric disorder and moderate acne vulgaris. Drugs. 2007;67:1749-1765.
78. Association of Reproductive Health Professionals. Extended regimen oral contraceptives. Harris Poll, June 14-17, 2002.
79. den Tonkelaar I, Odden BJ. Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone therapy replacement use. Contraception. 1999;59:357-362.
80. Omar H, Kives S, Allen L. Extended use of the oral contraceptive pill-is it an acceptable option for the adolescent? J Pediatr Adolesc Gynecol. 2005;18:285-288.
81. Sulak PJ, Buckley T, Kuehl TJ. Attitudes and prescribing preferences of health care professionals in the United States regarding use of extended-cycle oral contraceptives. Contraception. 2006;73:41-45.
82. Schwartz JL, Creinen MD, Pymar HC. The trimonthly combination oral contraceptive regimen: is it cost effective? Contraception. 1999;60:263-267.
83. Kwiecien M, Edelman A, Nichols MD, Jensen JF. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial. Contraception. 2003;67:9-13.
84. Miller L, Hughes JP. Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial. Obstet Gynecol. 2003; 101:653-661.
85. Archer DF, Jensen JT, Johnson JV, Borisuted H, Grubb GS, Constantine GD. Evaluation of a continuous regimen of levonorgestrel/ ethinyl estradiol: phase 3 study results. Contraception. 2006;74:439-445.
86. Johnson JV, Grubbs GS, Constantine GD. Endometrial histology following 1 year of a continuous daily regimen of levonorgestrel 90 microg/ethinyl oestradiol 20 microg. Contraception. 2007;75:23-26.
87. Kaiser Daily Women's Health Policy Report 5/22/2007.
88. Edelman A, Gallo MF, Nichols MD, Jensen JT, Schulz KF, Grimes DA. Continuous versus cyclic use of combined oral contraceptives for contraception: systematic Cochrane review of randomized controlled trials. Hum Reprod. 2006;21:573-578.
89. Steinauer J, Autry AM. Extended cycle combined hormonal contraception. Obstet Gynecol Clin North Am. 2007;34:43-55.